The Phase 3 trial NCT03353831, investigating atezolizumab in patients with recurrent ovarian carcinoma, reached its primary completion on 2025-03-11. This study evaluated atezolizumab in combination with bevacizumab and chemotherapy compared to placebo with bevacizumab and chemotherapy.

Background

The trial, titled "Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer," is a Phase 3, randomized, partially blinded, multicenter study. Its objective is to assess the efficacy and safety of atezolizumab plus bevacizumab and chemotherapy in patients experiencing a first or second relapse of ovarian, fallopian tube, or primary peritoneal cancer within 6 months after platinum-based chemotherapy, or a third relapse.

Trial design

The study (NCT03353831) is a Phase 3, randomized, partially blinded, multicenter trial. It enrolled 574 participants diagnosed with recurrent ovarian carcinoma, specifically ovarian, fallopian tube, or primary peritoneal cancer. The interventions studied included bevacizumab, atezolizumab, chemotherapy, and placebos. The trial compared an investigational arm of atezolizumab plus bevacizumab and chemotherapy against a control arm of placebo plus bevacizumab and chemotherapy.

What this means

The primary completion of the NCT03353831 trial signifies that the main data collection phase for the study has concluded. While specific efficacy and safety results are not yet available, this milestone indicates progress in evaluating atezolizumab as a potential treatment option for patients with recurrent ovarian carcinoma. The findings from this trial will provide important insights into the role of atezolizumab in combination with established therapies for this patient population.

Source

Information regarding the primary completion of this trial was sourced from ClinicalTrials.gov, a public database of clinical studies. The record for study NCT03353831, titled "Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer," was updated to reflect primary completion on 2025-03-11 on clinicaltrials.gov.